APA (7th ed.) Citation

Haynes, J. (2018). Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer. The American Association for Cancer Research (AACR).

Chicago Style (17th ed.) Citation

Haynes, J. Administration of Hypoxia-Activated Prodrug Evofosfamide After Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer. The American Association for Cancer Research (AACR), 2018.

MLA (9th ed.) Citation

Haynes, J. Administration of Hypoxia-Activated Prodrug Evofosfamide After Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer. The American Association for Cancer Research (AACR), 2018.